BRPI0806863B8 - uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv - Google Patents
uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hivInfo
- Publication number
- BRPI0806863B8 BRPI0806863B8 BRPI0806863A BRPI0806863A BRPI0806863B8 BR PI0806863 B8 BRPI0806863 B8 BR PI0806863B8 BR PI0806863 A BRPI0806863 A BR PI0806863A BR PI0806863 A BRPI0806863 A BR PI0806863A BR PI0806863 B8 BRPI0806863 B8 BR PI0806863B8
- Authority
- BR
- Brazil
- Prior art keywords
- phorbol ester
- treat
- drug
- preparation
- prevent
- Prior art date
Links
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 title abstract 5
- 239000002644 phorbol ester Substances 0.000 title abstract 5
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- 150000004633 phorbol derivatives Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/46—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom rings with more than six members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/013—Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89881007P | 2007-01-31 | 2007-01-31 | |
| US60/898,810 | 2007-01-31 | ||
| PCT/US2008/001299 WO2008094657A1 (en) | 2007-01-31 | 2008-01-30 | Compositions and methods of use of phorbol esters |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0806863A2 BRPI0806863A2 (pt) | 2014-04-29 |
| BRPI0806863B1 BRPI0806863B1 (pt) | 2021-02-02 |
| BRPI0806863B8 true BRPI0806863B8 (pt) | 2021-05-25 |
Family
ID=39674428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0806863A BRPI0806863B8 (pt) | 2007-01-31 | 2008-01-30 | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv |
Country Status (24)
| Country | Link |
|---|---|
| US (8) | US20080226589A1 (enExample) |
| EP (2) | EP2368555B1 (enExample) |
| JP (5) | JP2010516813A (enExample) |
| KR (2) | KR101187859B1 (enExample) |
| CN (1) | CN101677542B (enExample) |
| AU (1) | AU2008211081A1 (enExample) |
| BR (1) | BRPI0806863B8 (enExample) |
| CA (1) | CA2676551C (enExample) |
| CY (1) | CY1117938T1 (enExample) |
| ES (1) | ES2584327T3 (enExample) |
| HR (1) | HRP20160902T1 (enExample) |
| HU (1) | HUE029954T2 (enExample) |
| IL (1) | IL200141A0 (enExample) |
| LT (1) | LT2368555T (enExample) |
| MX (1) | MX2009008179A (enExample) |
| MY (2) | MY172303A (enExample) |
| PH (1) | PH12017502257A1 (enExample) |
| PL (1) | PL2368555T3 (enExample) |
| PT (1) | PT2368555T (enExample) |
| RS (1) | RS54988B1 (enExample) |
| RU (1) | RU2472511C2 (enExample) |
| SI (1) | SI2368555T1 (enExample) |
| WO (1) | WO2008094657A1 (enExample) |
| ZA (1) | ZA200905273B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9974764B2 (en) | 2007-01-31 | 2018-05-22 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters in the treatment of neoplasms |
| US9533938B2 (en) | 2007-01-31 | 2017-01-03 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| US9636317B2 (en) | 2007-01-31 | 2017-05-02 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters |
| US11696908B2 (en) | 2007-01-31 | 2023-07-11 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters |
| ES2584327T3 (es) | 2007-01-31 | 2016-09-27 | Biosuccess Biotech Company | Composiciones y métodos de uso de ésteres de forbol |
| US10369222B2 (en) | 2012-01-18 | 2019-08-06 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| US11564901B2 (en) | 2007-01-31 | 2023-01-31 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters |
| EP4585589A3 (en) | 2008-12-03 | 2025-11-19 | The Scripps Research Institute | Stem cell cultures |
| US8575216B2 (en) * | 2009-08-04 | 2013-11-05 | Rutgers, The State University Of New Jersey | Method of treatment for acute myelogenous leukemia |
| TWI619494B (zh) * | 2013-01-18 | 2018-04-01 | 華鴻新藥股份有限公司 | 巴豆酯之組成物及使用方法 |
| BR112014017716A8 (pt) * | 2012-01-18 | 2021-03-02 | Biosuccess Biotech Co Ltd | composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol |
| US10099996B2 (en) | 2012-01-18 | 2018-10-16 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbol esters in the treatment of neoplasms |
| US9550722B2 (en) | 2012-01-18 | 2017-01-24 | Biosuccess Biotech Co. Ltd. | Compositions and methods of use of phorbal esters for the treatment of stroke |
| RU2488400C1 (ru) * | 2012-03-12 | 2013-07-27 | Вячеслав Владимирович Чеботарёв | Способ превентивного дифференцированного лечения лиц, контактных с больными заразной формой сифилиса |
| CA2891294A1 (en) | 2012-11-15 | 2014-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating patients infected with hiv and htlv |
| TWI750481B (zh) * | 2013-01-18 | 2021-12-21 | 美商華鴻新藥股份有限公司 | 用於中風治療之巴豆酯組成物及使用方法 |
| MA40904A (fr) * | 2014-11-03 | 2017-09-12 | Hygeia Tech Inc | Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US6080784A (en) * | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
| EP0531413B1 (en) | 1990-05-30 | 1998-08-26 | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE | An antiviral composition containing prostratin |
| ATE185133T1 (de) | 1990-07-30 | 1999-10-15 | Procyon Pharm Inc | Proteinkinase-c-modulatoren mit entzündungshemmender und antiviraler aktivität |
| RU2197964C2 (ru) * | 1995-04-12 | 2003-02-10 | Дзе Проктер Энд Гэмбл Компани | Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций |
| US6184248B1 (en) | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| GB9620390D0 (en) | 1996-09-30 | 1996-11-13 | Eisai London Res Lab Ltd | Substances and their uses |
| US6063814A (en) * | 1997-04-14 | 2000-05-16 | Chang; Richard L. | Phorbol esters as anti-neoplastic and white blood cell elevating agents |
| CA2237877A1 (en) | 1998-06-26 | 1999-12-26 | Anthony Paolitto | Chest retractor for performing cardiac surgery |
| JP4110347B2 (ja) | 1999-11-05 | 2008-07-02 | 大鵬薬品工業株式会社 | 抗ｈｉｖ剤 |
| JP2001139468A (ja) * | 1999-11-11 | 2001-05-22 | Lead Chemical Co Ltd | 抗ウイルス作用を有するホルボール誘導体 |
| AU4317500A (en) * | 2000-05-02 | 2001-11-12 | Lead Chemical Co., Ltd. | Antibiral compositions containing phorbol derivatives as the main active ingredient |
| AU2001282717A1 (en) | 2000-07-28 | 2002-02-13 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
| US20070009529A1 (en) | 2002-03-26 | 2007-01-11 | New York University | Agents that dissolve arterial thrombi |
| US20080004332A1 (en) | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| DE10244453A1 (de) | 2002-09-24 | 2004-04-01 | Phenomiques Gmbh | Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten |
| US7662852B2 (en) | 2003-05-22 | 2010-02-16 | Lead Chemical Co., Ltd. | Compounds and preparations having antiviral effect |
| JP4006645B2 (ja) * | 2003-08-27 | 2007-11-14 | トヨタ自動車株式会社 | 排ガス浄化装置 |
| JP2005179201A (ja) * | 2003-12-16 | 2005-07-07 | Japan Science & Technology Agency | 抗ｈｉｖ化合物とその利用 |
| JP2008069182A (ja) | 2004-03-24 | 2008-03-27 | Yamasa Shoyu Co Ltd | ４’−ｃ−置換−２−ハロアデノシン誘導体 |
| CA2502109C (en) * | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| EP1924548B1 (en) * | 2005-07-13 | 2018-03-28 | Salvia Sciences, Inc. | Ester prodrugs of prostratin and related phorbol compounds |
| WO2008024490A2 (en) | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
| ES2584327T3 (es) | 2007-01-31 | 2016-09-27 | Biosuccess Biotech Company | Composiciones y métodos de uso de ésteres de forbol |
| EP2030631A1 (en) | 2007-08-31 | 2009-03-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for treating peripheral and cardiovascular diseases via modulation of arteriogenesis |
| US8575216B2 (en) | 2009-08-04 | 2013-11-05 | Rutgers, The State University Of New Jersey | Method of treatment for acute myelogenous leukemia |
| KR101144327B1 (ko) | 2010-04-02 | 2012-05-11 | 한국과학기술연구원 | Ｐｋｃ 작용 활성제를 유효성분으로 함유하는 압상스 간질의 예방 및 치료용 조성물 |
| WO2011127288A2 (en) | 2010-04-07 | 2011-10-13 | La Jolla Institute For Allergy And Immunology | Methods and uses of nur77 and nur77 agonists to modulate macrophages and monocytes, and treat inflammation, inflammatory disease and cardiovascular disease |
| WO2011144901A1 (en) | 2010-05-20 | 2011-11-24 | The University Of Newcastle Upon Tyne | Expansion and directed differentiation of epidermal neural crest stem cells |
| BR112014017716A8 (pt) | 2012-01-18 | 2021-03-02 | Biosuccess Biotech Co Ltd | composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol |
| JP5738207B2 (ja) * | 2012-01-27 | 2015-06-17 | 三菱電機株式会社 | 圧縮機、冷蔵庫、機器 |
-
2008
- 2008-01-30 ES ES10015894.8T patent/ES2584327T3/es active Active
- 2008-01-30 RS RS20160571A patent/RS54988B1/sr unknown
- 2008-01-30 HU HUE10015894A patent/HUE029954T2/en unknown
- 2008-01-30 KR KR1020097018188A patent/KR101187859B1/ko not_active Expired - Fee Related
- 2008-01-30 MY MYPI20093116A patent/MY172303A/en unknown
- 2008-01-30 EP EP10015894.8A patent/EP2368555B1/en active Active
- 2008-01-30 SI SI200831648A patent/SI2368555T1/sl unknown
- 2008-01-30 CA CA2676551A patent/CA2676551C/en not_active Expired - Fee Related
- 2008-01-30 JP JP2009548304A patent/JP2010516813A/ja active Pending
- 2008-01-30 KR KR1020127014050A patent/KR20120091267A/ko not_active Ceased
- 2008-01-30 PL PL10015894T patent/PL2368555T3/pl unknown
- 2008-01-30 WO PCT/US2008/001299 patent/WO2008094657A1/en not_active Ceased
- 2008-01-30 MY MYPI2017001013A patent/MY186986A/en unknown
- 2008-01-30 LT LTEP10015894.8T patent/LT2368555T/lt unknown
- 2008-01-30 CN CN200880010630.XA patent/CN101677542B/zh not_active Expired - Fee Related
- 2008-01-30 PT PT100158948T patent/PT2368555T/pt unknown
- 2008-01-30 AU AU2008211081A patent/AU2008211081A1/en not_active Abandoned
- 2008-01-30 RU RU2009132345/15A patent/RU2472511C2/ru active
- 2008-01-30 BR BRPI0806863A patent/BRPI0806863B8/pt not_active IP Right Cessation
- 2008-01-30 MX MX2009008179A patent/MX2009008179A/es active IP Right Grant
- 2008-01-30 EP EP08725016A patent/EP2170053A4/en not_active Withdrawn
- 2008-01-31 US US12/023,753 patent/US20080226589A1/en not_active Abandoned
-
2009
- 2009-07-29 IL IL200141A patent/IL200141A0/en active IP Right Grant
- 2009-07-29 ZA ZA200905273A patent/ZA200905273B/xx unknown
-
2013
- 2013-03-11 US US13/794,467 patent/US9132113B2/en not_active Expired - Fee Related
- 2013-07-26 JP JP2013155621A patent/JP5923068B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-20 US US14/545,061 patent/US20150202178A1/en not_active Abandoned
- 2015-08-12 US US14/824,688 patent/US9603825B2/en not_active Expired - Fee Related
- 2015-09-03 US US14/756,365 patent/US20150374656A1/en not_active Abandoned
-
2016
- 2016-01-08 JP JP2016002526A patent/JP2016056192A/ja active Pending
- 2016-07-19 CY CY20161100709T patent/CY1117938T1/el unknown
- 2016-07-19 HR HRP20160902TT patent/HRP20160902T1/hr unknown
-
2017
- 2017-02-10 US US15/429,311 patent/US9907775B2/en active Active
- 2017-12-08 JP JP2017235841A patent/JP6616387B2/ja active Active
- 2017-12-11 PH PH12017502257A patent/PH12017502257A1/en unknown
-
2018
- 2018-11-05 US US16/180,881 patent/US20190071387A1/en not_active Abandoned
-
2019
- 2019-11-07 JP JP2019202032A patent/JP2020037569A/ja active Pending
-
2020
- 2020-03-09 US US16/812,770 patent/US20200207696A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
| BRPI0916286B8 (pt) | amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica | |
| CR11455A (es) | Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades | |
| UY30215A1 (es) | Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones | |
| BRPI0508540A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| UY32919A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos | |
| GT200900095A (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas. | |
| UY31080A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis | |
| CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| BRPI0915064B8 (pt) | derivados de quinoxalinadiona, seus usos, e medicamentos | |
| CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
| UY31952A (es) | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim | |
| CL2008001839A1 (es) | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. | |
| BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CL2008003822A1 (es) | Compuestos derivados de n1-(2-tiazolil)-1,2-dicarboxamida pirrolidina; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades mejoradas por la inhibicion de la fosfatidilinositol-3-cinasa, como el cancer. | |
| BRPI0714803B8 (pt) | compostos peptidomiméticos de smac, seus usos, e composição farmacêutica | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| CL2007001648A1 (es) | Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina. | |
| CL2008003473A1 (es) | Compuestos derivados de fenilpiperidina sustituidos por heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso en el tratamiento del trastorno cardiovasculares, tromboembolicos y tumorales; usos in vitro. | |
| UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
| BRPI0907789A2 (pt) | derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos | |
| DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/00 , A01N 43/46 , A61K 31/55 Ipc: A01N 63/00 (2020.01), A01N 43/46 (2006.01), A61K 3 |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/02/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2707 DE 22-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |